An expanded access program is underway for RT001 in some people with ALS
Original source
RT001 (opens in a new tab)An expanded access program is allowing people with ALS at certain clinics to try RT001 free of charge. The program is intended to provide data for planning a possible future clinical trial. There is currently very little evidence about RT001’s safety or effectiveness in people with ALS.
Why this matters
This may give eligible people with ALS access to RT001, but it does not establish that the compound works or change standard treatment. The program’s data could help researchers decide whether and how to study RT001 in a future trial.
Limitations and context
This information comes from an independent ALS Untangled expert review, not a primary clinical-trial report. The review says evidence in people with ALS was very limited at the time of publication. Lower doses appeared tolerated in a small Friedreich’s ataxia trial, while higher doses could cause nausea and diarrhea, but those findings were not established in ALS. The expanded access program is not a controlled trial and cannot by itself show effectiveness.